Gamifant (emapalumab) recommended for approval in China for treatment of primary haemophagocytic lymphohistiocytosis (HLH)
Sobi® today announces that the Center for Drug Evaluation (CDE) has recommended approval of Gamifant® to the National Medical Products Administration of China (NMPA). The indication is for treatment of adult and paediatric (newborn and older) patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance to conventional HLH therapy. Primary HLH is an ultra-rare, life-threatening, hyperinflammatory disorder, characterised by uncontrolled activation of the immune system. Morbidity and mortality are high due to lack of